GlassScriptPhysician profile
Frank O Boyd
NPI 1841480613
$1,204.34
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $283 · 2021: $222.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349.91 | 2019-2021 | |
| Mylan Specialty L.P. | $158.86 | 2019 | |
| Amgen INC. | $119.33 | 2019-2020 | |
| Medtronic, INC. | $87.42 | 2021 | |
| Glaxosmithkline, LLC. | $83.87 | 2019-2021 | |
| Allergan, INC. | $68.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $56.95 | 2019-2021 | |
| Pfizer INC. | $54.69 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $34.18 | 2020-2021 | |
| Radius Health, INC. | $33.42 | 2019-2020 | |
| Abbvie INC. | $32.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2019 | |
| Amarin Pharma, INC. | $18.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.82 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.